| abstract |
Corticosteroid formulations are provided in microparticles for use in the treatment of pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and to decelerate, stop or reverse tissue damage structures caused by an inflammatory disease, for example damage to joint and / or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis; Microparticle corticosteroid formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by a clinically minor or non-measurable effect on endogenous cortisol production. |